TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07328529: Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Sponsor: Azevan Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,108,800

Rescue Site Savings

+$4,017,200

Unlock Full NCT07328529 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07328529 Rescue Dossier →